Therefore, KRAS-mutant CRC can serve as a good research model to study the molecular mechanism of anti-EGFR therapy as well as to establish and discover new therapeutic strategies for reverting the resistance of KRAS-mutant CRC to cetuximab. This evidence concerns the gene KRAS and colorectal carcinoma.